Generic Name: sorafenib

Pronunciation: N/A

Abbreviation: N/A

Other Market Name: N/A

Drug Class: Targeted Therapy Medications

Company: Bayer

Approval Status: Approved

Generic Version Available: No

Experimental Code: N/A

Drug Indication

Nexavar is a multikinase inhibitor approved for treatment of inoperable liver cancer that can't be surgically removed, advanced kidney cancer and recurrent or metastatic thyroid cancer.

General Info

Nexavar is a kinase inhibitor that blocks the action of several enzymes, including VEGFR, BRAF and RET, that play a role in cell growth and development of blood vessels that feed tumors.

The Phase III SHARP trials showed that Nexavar delays disease progression and improves survival in people with liver cancer. The TARGET and DECISION trials showed that Nexavar improves progression-free survival for people with kidney cancer and thyroid cancer. It was first approved in 2005.


Dosing Info:

Nexavar is taken as a pill twice daily without food.

Side Effects

Common side effects include diarrhea, fatigue, hair loss, loss of appetite, weight loss, nausea, high blood pressure, skin rash and hand-foot syndrome (palmar-plantar erythrodysesthesia), with redness, swelling and pain on the palms of the hands and soles of the feet. Potential serious side effects may include cardiovascular problems, severe bleeding (hemorrhage), severe hypertension and severe skin reactions. Nexavar may cause fetal harm if used during pregnancy.

For More Info:

Patient Assistance Program Info:

Last Reviewed: December 15, 2018